On 9 September, the drug development company focused on rare diseases announced that it would be presenting data from multiple clinical and pre-clinical studies evaluating its rare disease drug candidate, ShigamabTM, as a potential treatment for Shiga toxin E. coli induced hemolytic uremic syndrome (sHUS). We have now had an opportunity to review some of this data. The data was presented at the International Symposium on Shiga toxin Producing Escherichia Coli conference in Boston and we belie
21 Sep 2015
Compelling databank building for ShigamabTM
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Compelling databank building for ShigamabTM
Blue Star Capital Plc (BLU:LON) | 0.0 0 0.0% | Mkt Cap: 1.53m
- Published:
21 Sep 2015 -
Author:
Derren Nathan -
Pages:
6
On 9 September, the drug development company focused on rare diseases announced that it would be presenting data from multiple clinical and pre-clinical studies evaluating its rare disease drug candidate, ShigamabTM, as a potential treatment for Shiga toxin E. coli induced hemolytic uremic syndrome (sHUS). We have now had an opportunity to review some of this data. The data was presented at the International Symposium on Shiga toxin Producing Escherichia Coli conference in Boston and we belie